Zihan Dai, Masashi Miyashita, Eric Tsz-Chun Poon, Xiao Yu Tian, Angus Pak-Hung Yu, Cindy Hui-Ping Sit, Stephen Heung-Sang Wong
Journal: Nature communications 2025;16(1):10659
PMID: 41309556
Obesity poses a significant public health challenge among middle-aged women, driven by physiological changes associated with aging and menopause. This parallel-group, assessor-blinded, four-arm randomized controlled trial investigated the effects of 12-week 8-hour flexible time-restricted eating (flexTRE) and aerobic exercise (EX), alone or in combination (flexTRE+EX), on body composition and metabolic health in a free-living setting. Participant enrolment began on September 1st 2023 and data collection was completed on July 1st 2024. Conducted at a single research site in Hong Kong, the trial enrolled women aged 40-60 years with overweight/obesity. Participants were randomized in a 1:1:1:1 ratio to a flexTRE, EX, flexTRE+EX, or control (CON) group (n = 26 per group), with all 104 participants included in the final intention-to-treat analysis. Outcomes were assessed at baseline, and week 12. The primary outcome was fat mass. The flexTRE+EX group achieved the greatest fat mass reduction compared to the CON group (adjusted mean difference [99% Confidence Interval] -2.85 kg [-4.01 to -1.69]), and additional benefit over the flexTRE group alone (-1.56 kg [-2.74 to -0.38]), and the EX group alone (-2.01 kg [-3.21 to -0.81]). Secondary outcomes were reported in the main text. No serious adverse events were reported, and adherence was high (83%-87%) across intervention groups. These findings suggest that the combined approach effectively reduces fat mass and enhances related metabolic parameters, providing a feasible and effective strategy in middle-aged women facing overweight/obesity. Trial registration: ChiCTR2300074846.
© 2025. The Author(s).
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.